HALB

Home>Tag:HALB
Sep 14 2020

Halberd Corporation Outlines Multi-Phase $1.4 M Covid-19 Program in Partnership With ASU

By |2020-09-13T20:36:48-04:00September 14th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based ...

Sep 8 2020

Halberd Corporation Research on Covid-19 Treatment Development Begins at ASU

By |2020-09-08T11:19:17-04:00September 8th, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of ...

Sep 2 2020

Why Halberd Corporation Selected ASU And Where They Stand Among Other Universities

By |2020-09-02T08:00:19-04:00September 2nd, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services ...

Aug 31 2020

Halberd Selects Arizona State University (ASU) to Develop Its Patented Covid-19 Treatment(s)

By |2020-08-31T08:00:31-04:00August 31st, 2020|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments.  The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications ...

Jul 7 2020

COVID-19 Cytokine Storm, Coronavirus’ Deadliest Stage – Halberd’s US Patent Pending Treatment Now Explained!

By |2020-07-06T19:47:51-04:00July 7th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, July 7, 2020 – Halberd Corp. (OTC PINK: "HALB") today explains the second of three (3) COVID -19 (Coronavirus) patent pending treatments - “Method for Treating Covid-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in Covid-19 Patients” - which was filed with the U.S. Patent and Trademark Office on ...

Jun 15 2020

Halberd Designated “Pink Current Information” by OTC and Continues Technology Progress

By |2020-06-21T04:55:39-04:00June 15th, 2020|Featured, News, Technology|0 Comments

Jackson Center, PA, June 15, 2020 –Halberd Corporation (OTC Pink: HALB) announced that OTC Markets has completed its background investigation and analysis of all filings by Halberd Corporation and now designates Halberd Corporation as "Pink Current Information". William A. Hartman, newly appointed Chairman, President and CEO explains, “Now that Halberd has been designated by OTC ...

Go to Top